Recruiting
Phase 1
Phase 2

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Sponsor:

IDEAYA Biosciences

Code:

NCT03947385

Conditions

Metastatic Uveal Melanoma

Cutaneous Melanoma

Colorectal Cancer

Other Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IDE196

Binimetinib

Crizotinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information